- Previous Close
14.32 - Open
14.33 - Bid 14.56 x 200
- Ask 14.71 x 100
- Day's Range
14.33 - 15.08 - 52 Week Range
3.35 - 16.50 - Volume
292,301 - Avg. Volume
1,087,888 - Market Cap (intraday)
1.416B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.47 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.67
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ars-pharma.comRecent News: SPRY
View More
Performance Overview: SPRY
Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPRY
View MoreValuation Measures
Market Cap
1.39B
Enterprise Value
1.17B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.76k
Price/Book (mrq)
6.45
Enterprise Value/Revenue
2.34k
Enterprise Value/EBITDA
-9.88
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.75%
Return on Equity (ttm)
-19.34%
Revenue (ttm)
500k
Net Income Avi to Common (ttm)
-44.84M
Diluted EPS (ttm)
-0.47
Balance Sheet and Cash Flow
Total Cash (mrq)
218.74M
Total Debt/Equity (mrq)
0.07%
Levered Free Cash Flow (ttm)
-26.33M
Research Analysis: SPRY
View MoreCompany Insights: SPRY
SPRY does not have Company Insights